SGP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SpyGlass Pharma Inc (SGP) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has significant potential in the glaucoma and cataract market, the current technical indicators are bearish, and the financial performance shows profitability challenges. It is advisable to monitor the stock for better entry points or further developments in its clinical trials.
The technical indicators are bearish. The MACD is negative and contracting, RSI is neutral at 42.314, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The pre-market price of $25.15 is below the pivot level of $25.532, with key support at $23.321 and resistance at $27.744.
Analysts have unanimously initiated Buy ratings with price targets ranging from $37 to $62, citing the disruptive potential of the BIM-IOL system in the glaucoma and cataract surgery market.
The company raised $172.5 million in its IPO to fund Phase 3 trials, with positive Phase 1/2 results showing 97% of participants free from IOP-lowering eye drops after 12 months.
The BIM-IOL system addresses a $13 billion U.S. market opportunity and could generate $2 billion in peak sales.
The company reported a Q4 2025 GAAP EPS of -$5.72, highlighting profitability challenges.
Liquidity pressures remain despite $107.4 million in cash reserves.
The stock has no significant hedge fund or insider trading trends, indicating a lack of strong institutional or insider confidence.
SpyGlass Pharma reported a Q4 2025 GAAP EPS of -$5.72, reflecting ongoing profitability challenges. The company has $107.4 million in cash reserves, which may support its clinical trials but highlights liquidity pressures.
Analysts are highly optimistic, with Buy ratings from H.C. Wainwright, Stifel, Citi, Jefferies, and Leerink. Price targets range from $37 to $62, with analysts citing the large market opportunity, the disruptive potential of the BIM-IOL system, and positive Phase 1/2 trial results. However, the stock has already rallied 70% since its IPO, which may limit immediate upside potential.
